Interleukin-2 (IL-2) is a pluripotent cytokine that regulates the immune system’s response. The IL-2 receptor (IL-2R) is a heterotrimeric protein that binds to IL-2 and reacts to it on the ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

Interleukin 2 (IL-2) is the only systemic treatment currently available that is capable of curing patients with metastatic renal cell cancer (RCC). The first indications that IL-2 could mediate ...

After nabbing an FDA approval last summer for its T-cell lymphoma treatment Lymphir, Citius Oncology is eyeing strategic ...

Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced an ag ...

Australian immuno-oncology company Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T ...

The aberrant immune response against self-antigens occurring in autoimmune diseases involves dysregulation of members of intracellular signal transduction pathways such as interleukin-2-inducible T ...